EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Other Sources: 6

Hyaluronic acid (oral)

Also called: hyaluronan, sodium hyaluronate, oral hyaluronan

Hyaluronic acid (hyaluronan) is a large molecule in cartilage and synovial fluid, built from alternating N-acetyl-D-glucosamine and D-glucuronic acid units, and plays a role in skin water content. This entry covers oral supplements, not injections or skin creams.

Category
Other
Forms
Hyaluronic acid or sodium hyaluronate taken by mouth as capsules or drinks
Strongest evidence
B Some positive trials
Reviewed
2026-10-30

Class 2 Moderately studied in people. A 2022 meta-analysis (Front Nutr) pooled 4 RCTs (196 healthy adults) of oral hyaluronan as a single preparation versus placebo for skin hydration. [1]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

3 topics studied2 body areas · strongest grade B

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Hyaluronic acid (oral) does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Hyaluronic acid (oral), evidence grade and finding
Topic studiedGradeWhat the evidence shows
Skin hydration in healthy adultsBA meta-analysis of 4 RCTs (196 participants, 4–12 weeks) found improved skin hydration versus placebo (SMD +0.40); trial designs were poorly reported and one trial had high risk of other bias. [1]
Skin photoaging and elasticityCA 2025 meta-analysis identified 4 studies (178 participants); pooling 2 (100 participants) found no significant difference from placebo in overall skin elasticity, with high heterogeneity. [2]
Osteoarthritis and low back painCA 2024 systematic review of 11 trials (597 patients) found improvement in 9; only 2 trials gave oral hyaluronic acid alone, while 9 combined it with substances such as glucosamine, chondroitin or collagen. [3]

Main constituents: Hyaluronic acid, a polymer of alternating N-acetyl-D-glucosamine and D-glucuronic acid units [3]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Skin hydration trials: 120 mg/day (three RCTs) or 200 mg/day (one RCT) of oral hyaluronan for 4 to 12 weeks. [1]
  • Osteoarthritis and low back pain trials: 30 mg to 300 mg/day, with follow-up of 4 weeks to 12 months. [3]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked. The profile notes other test results.

    Details and sources
  • FDA new dietary ingredient notifications
    2 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • In the 2024 review, adverse effects in the oral hyaluronic acid groups were reported in 2 of 11 trials and were mild; one 12-month trial reported gastric discomfort (2), reflux esophagitis (1) and appetite loss (1) in the hyaluronic acid group. [3]
  • The 2022 skin-moisturizing meta-analysis reported that all food supplements studied were safe during the trials (normally 24 weeks or less). [1]
Regulation

Regulatory status

  • US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [5]
  • US: FDA's published NDI notification list has 2 entries naming hyaluronic acid or sodium hyaluronate (NDI 479 and NDI 480, both submitted 2007-09-07). [6]
  • US: FDA's GRAS Notice Inventory lists GRN 976 (sodium hyaluronate), closed May 24, 2021: at the notifier's request, FDA ceased to evaluate the notice. [4]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Hyaluronic acid (hyaluronan), a large molecule of alternating N-acetyl-D-glucosamine and D-glucuronic acid units; the review states a molecular weight ranging from 6,500 to 10,900 kDa Polysaccharides [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 2 entries naming hyaluronic acid or sodium hyaluronate (earliest NDI 479 submitted 2007-09-07; most recent NDI 480 submitted 2007-09-07). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P2]
  • FDA's GRAS Notice Inventory lists GRN 976 (sodium hyaluronate), closed May 24, 2021, with the letter: at the notifier's request, FDA ceased to evaluate this notice. [P3]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of hyaluronic acid was found (IARC Monographs cumulative cross index, Volumes 1 to 142, and NTP technical reports index TR-001 to TR-606, checked 2026-10-30). [P4]
  • The NTP Technical Reports index lists no 2-year study of hyaluronic acid (checked 2026-10-30). [P5]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • No published information found in the sources checked.

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P6]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. de Carvalho JF, Davidson J. Oral hyaluronic acid in osteoarthritis and low back pain: a systematic review. Mediterr J Rheumatol 2024;35(4):557-562 (PMID 39886281), 2024-12-31. pubmed.ncbi.nlm.nih.gov
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. FDA. GRAS Notice Inventory: GRN No. 976, Sodium hyaluronate (closed May 24, 2021), 2021-05-24. hfpappexternal.fda.gov
  4. IARC Monographs. Cumulative Cross Index to IARC Monographs Volumes 1 to 142 (PDF, retrieved 2026-10-30), 2026-10-30. monographs.iarc.who.int
  5. National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-30. ntp.niehs.nih.gov
  6. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/29/2026), 2026-10-29. ecfr.gov
Sources

Sources

  1. Sun Q, et al. Effectiveness of dietary supplement for skin moisturizing in healthy adults: a systematic review and meta-analysis of randomized controlled trials. Front Nutr 2022;9:895192 (PMID 35719159), 2022-06-02. pubmed.ncbi.nlm.nih.gov
  2. Yang Q, et al. Effectiveness of dietary supplements for skin photoaging in healthy adults: a systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne) 2025;12:1582946 (PMID 40761858), 2025-07-21. pubmed.ncbi.nlm.nih.gov
  3. de Carvalho JF, Davidson J. Oral hyaluronic acid in osteoarthritis and low back pain: a systematic review. Mediterr J Rheumatol 2024;35(4):557-562 (PMID 39886281), 2024-12-31. pubmed.ncbi.nlm.nih.gov
  4. FDA. GRAS Notice Inventory: GRN No. 976, Sodium hyaluronate (closed May 24, 2021), 2021-05-24. hfpappexternal.fda.gov
  5. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (Content current as of 08/27/2026), 2026-08-27. fda.gov
  6. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.